通过遗传距离分析快速评估COVID-19疫苗对SARS-CoV-2变异株症状性感染的保护效果
基于49项研究的78个疫苗效力或效果数据及31个地区1,984,241条SARS-CoV-2序列,分析病毒与疫苗株遗传距离与症状性感染保护效果的关系。RBD遗传距离可高度预测疫苗保护力,在混合效应模型中解释86.3%(P=0.038)和87.9%(P=0.006)的VE变化。该框架可实时预测新变异株的疫苗保护并提供快速评估方法。
要点
- RBD遗传距离可高度预测疫苗对症状性感染的保护效果
- mRNA疫苗平台对Delta变异株预测VE为82.8%,与观察性研究报告的83.0%高度吻合
- Omicron四个亚系中,mRNA疫苗平台预测VE最高为BA.1、最低为BA.2
核心结论
- VE-GD框架可实时预测疫苗保护力,为疫苗部署和公共卫生应对提供快速评估新变异株的方法。
研究设计与样本
- 基于49项研究的78个疫苗效力或效果数据及31个地区采集的1,984,241条SARS-CoV-2序列,分析病毒与疫苗株遗传距离与症状性感染VE的关系。
主要发现
- SARS-CoV-2刺突蛋白受体结合域的遗传距离高度预测疫苗保护力,在基于疫苗平台的混合效应模型中解释86.3%(P=0.038)的VE变化,在基于制造商的模型中解释87.9%(P=0.006)。
- 应用VE-GD模型预测现有疫苗对新遗传变异株的保护力,经已发表真实世界和临床试验数据验证,预测VE与观察VE高度一致。
- 使用mRNA疫苗平台估计对Delta变异株的VE为82.8%(95%预测区间:68.7-96.0),与观察性研究报告的83.0%高度吻合。
- 使用mRNA疫苗平台,Omicron四个亚系中预测VE在11.9%至33.3%之间变化,对BA.1预测VE最高,对BA.2预测VE最低。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Timely evaluation of the protective effects of Coronavirus Disease 2019 (COVID-19) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern is urgently needed to inform pandemic control planning. Based on 78 vaccine efficacy or effectiveness (VE) data from 49 studies and 1,984,241 SARS-CoV-2 sequences collected from 31 regions, we analyzed the relationship between genetic distance (GD) of circulating viruses against the vaccine strain and VE against symptomatic infection. We found that the GD of the receptor-binding domain of the SARS-CoV-2 spike protein is highly predictive of vaccine protection and accounted for 86.3% (P = 0.038) of the VE change in a vaccine platform-based mixed-effects model and 87.9% (P = 0.006) in a manufacturer-based model. We applied the VE-GD model to predict protection mediated by existing vaccines against new genetic variants and validated the results by published real-world and clinical trial data, finding high concordance of predicted VE with observed VE. We estimated the VE against the Delta variant to be 82.8% (95% prediction interval: 68.7-96.0) using the mRNA vaccine platform, closely matching the reported VE of 83.0% from an observational study. Among the four sublineages of Omicron, the predicted VE varied between 11.9% and 33.3%, with the highest VE predicted against BA.1 and the lowest against BA.2, using the mRNA vaccine platform. The VE-GD framework enables predictions of vaccine protection in real time and offers a rapid evaluation method against novel variants that may inform vaccine deployment and public health responses.
引用
- Cao L, Lou J, Chan SY, et al. Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance. Nat Med. 2022. PMID: 35710987. doi:10.1038/s41591-022-01877-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。